+91 80 2808 2808

The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart

  • Posted by: BIOCON



Bengaluru, Karnataka, India, Jan 07, 2022

“The U.S. FDA has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Insulin Aspart filed by our partner Viatris (Mylan). We will respond to the CRL to satisfy the FDA’s requests. The CRL did not identify any outstanding scientific issues with the product.”

– Company Spokesperson, Biocon Biologics.

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>